ROS1 and non-small cell lung carcinoma: The patients with RET+ NSCLC in our cohort, otherwise, shared similar patterns of metastases to those with ALK+ or ROS1+ NSCLC, including high frequencies of pleural and bone metastases and lymphangitic carcinomatosis (Table 3; Figure 1).